Ashlea Hill
Family · Ruston, LANPI 1235413329
Payments from drug & device makers
Across 949 payments — averaging $177.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$41K
- Sanofi-aventis U.S. LLC$35K
- Dexcom, Inc.$28K
- Bayer$24K
- Lilly USA, LLC$20K
- Boehringer Ingelheim$6K
- plus $13K from 26 others
What the payments were for
- Consulting fees$14,2628%
- Speaking & faculty fees$123,67973%
- Travel & lodging$14,9119%
- Food & beverage$15,6799%
- Education$1600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 183 | $41,464 |
| Sanofi-aventis U.S. LLC | 72 | $35,309 |
| Dexcom, Inc. | 97 | $27,955 |
| Bayer | 117 | $24,135 |
| Lilly USA, LLC | 120 | $20,247 |
| Boehringer Ingelheim | 62 | $6,156 |
| Insulet Corporation | 48 | $3,047 |
| Eli Lilly | 6 | $2,897 |
| Sanofi US Services Inc. | 1 | $2,660 |
| BETA Bionics, Inc. | 27 | $1,139 |
| Abbott | 33 | $508 |
| Esperion Therapeutics, Inc. | 34 | $455 |
| AstraZeneca | 30 | $439 |
| Amgen(2 entities) | 21 | $361 |
| Amarin Pharma, Inc. | 18 | $331 |
| Medtronic | 19 | $299 |
| Corcept Therapeutics | 16 | $277 |
| Cequr Corporation | 1 | $169 |
| Averitas Pharma Inc. | 9 | $169 |
| Merck | 8 | $112 |
| Tandem Diabetes Care, Inc. | 5 | $105 |
| Xeris Pharmaceuticals, Inc. | 6 | $100 |
| GRT US Holding, Inc. | 6 | $94 |
| Sequel Med Tech, LLC | 1 | $58 |
| Alkermes, Inc. | 1 | $52 |
| Evoke Pharma, Inc. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 1 | $30 |
| Mannkind Corporation | 1 | $22 |
| Novartis | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $18 |
| AbbVie | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$37,307
- RYBELSUS$23,197
- Kerendia$22,098
- JARDIANCE$21,678
- DEXCOM G7 GSS (161)$20,891
- Ozempic$14,774
- DEXCOM G6 TRANSMITTER$5,469
- DEXCOM STELO GLUCOSE BIOSENSOR$3,449
- Omnipod$2,436
- iLet Bionic Pancreas$1,322
- iLet Insulin Infusion Kit Inset$244
- iLet Insulin Infusion Kit Contact Detach$244
- CeQur Simplicity$169
How this compares
$168,692 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 360 | $332,080 |
| MounjaroTirzepatide | 273 | $328,364 |
| OzempicSemaglutide | 231 | $262,468 |
| JardianceEmpagliflozin | 154 | $148,982 |
| KerendiaFinerenone | 117 | $104,232 |
| FarxigaDapagliflozin Propanediol | 134 | $86,528 |
| TrulicityDulaglutide | 66 | $65,827 |
| Humalog Kwikpen U-200Insulin Lispro | 28 | $53,635 |
| FiaspInsulin Aspart (Niacinamide) | 40 | $53,396 |
| TradjentaLinagliptin | 45 | $28,805 |
| JanuviaSitagliptin Phosphate | 39 | $28,262 |
| Tresiba Flextouch U-100Insulin Degludec | 56 | $26,945 |
| Humulin R U-500Insulin Regular, Human | 16 | $24,023 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $24,013 |
| RybelsusSemaglutide | 19 | $21,007 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $20,247 | $407,174400 claims |
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $41,464 | $354,212354 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Glyxambi, Synjardy Xr | $6,156 | $216,064245 claims |
| BayerKerendia | $24,135 | $104,232117 claims |
| AstraZenecaFarxiga | $439 | $86,528134 claims |
| MerckJanuvia | $112 | $28,26239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Ruston
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
- Kimberly RaoAlexandria$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.